GABA
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Looking at eye tracking’s potential for clinical trials
Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Cannabis compound rebalances signaling to quell seizures in mice
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
Cannabis compound rebalances signaling to quell seizures in mice
Single gene insufficient to account for dup15q, Angelman traits
UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.
Single gene insufficient to account for dup15q, Angelman traits
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Mouse studies cast astrocytes as stars of sensory perception
Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.
Mouse studies cast astrocytes as stars of sensory perception
Building a better drug
Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.
Portrait of a research field: astrocytes in autism
Long cast in supporting roles in the brain, astrocytes are now emerging as primary players in certain characteristics of autism and related conditions.
Portrait of a research field: astrocytes in autism
Explore more from The Transmitter
How inbreeding almost tanked an up-and-coming model of Alzheimer’s disease
But new genetic analyses and behavioral assays have made the Chilean degu a viable model again, researchers say.
How inbreeding almost tanked an up-and-coming model of Alzheimer’s disease
But new genetic analyses and behavioral assays have made the Chilean degu a viable model again, researchers say.
Sex-dependent cytokine release; KATNAL2 gene; auditory processing in fragile X syndrome
Here is a roundup of autism-related news and research spotted around the web for the week of 20 May.
Sex-dependent cytokine release; KATNAL2 gene; auditory processing in fragile X syndrome
Here is a roundup of autism-related news and research spotted around the web for the week of 20 May.
At the credit crossroads: Modern neuroscience needs a cultural shift to adopt new authorship practices
Old heuristics to acknowledge contributors—calling out first and last authors, with everyone else in between—don’t work well for large collaborative and interdisciplinary projects, yet they remain the default.
At the credit crossroads: Modern neuroscience needs a cultural shift to adopt new authorship practices
Old heuristics to acknowledge contributors—calling out first and last authors, with everyone else in between—don’t work well for large collaborative and interdisciplinary projects, yet they remain the default.